DCprime is the front-runner in the field of relapse vaccines, a new class of oncology vaccines administered after or in conjunction with standard of care therapy to delay or prevent disease recurrence. Our lead product is a whole-cell-based vaccine addressing blood cancers with a high risk of relapse. We are pursuing similar vaccination approaches for solid tumors. We believe relapse vaccines will improve survival by putting the patient’s immune system back in control.


DCprime bv
Galileïweg 8
2333 BD Leiden
T. +31 71 3322627


If you have any questions, please feel free to contact
DCprime directly or get in touch with our network management here. We are happy to assist and arrange a meeting with our members.